Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

GTBP
GT Biopharma Inc. Common Stock
stock NASDAQ

At Close
Sep 8, 2026 3:59:12 PM EDT
5.21USD+2061.826%(+4.97)86,418
0.2900Bid   7.57Ask   7.28Spread
Pre-market
Sep 4, 2026 9:19:30 AM EDT
0.2574USD+6.805%(+0.0164)0
After-hours
Sep 8, 2026 4:16:30 PM EDT
5.12USD-1.727%(-0.09)315
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
07:31AM EST  GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference   PR Newswire
Jan 6, 2022
04:30PM EST  GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule   PR Newswire
Dec 8, 2021
07:37AM EST  GT Biopharma Highlights Presentation At ESMO IO Congress 2021   Benzinga
07:31AM EST  GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021   PR Newswire
Nov 30, 2021
04:44PM EST  GT Biopharma Announces Abstract Accepted For European Society for Medical Oncology Dec. 8-11   Benzinga
07:31AM EST  Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021   PR Newswire
Nov 24, 2021
04:05PM EST  GT BioPharma to Host a Management Update Conference Call   PR Newswire
Nov 10, 2021
06:27PM EST  GT Biopharma Q3 EPS $(0.17) Up From $(0.64) YoY   Benzinga
04:10PM EST  GT BioPharma Reports Third Quarter 2021 Financial Results and Provides   PR Newswire
Nov 9, 2021
10:55AM EST  Mid-Afternoon Market Update: eHealth Drops Following Q3 Results; Autolus Therapeutics Shares Gain   Benzinga
10:48AM EST  Mid-Day Market Update: Trade Desk Jumps After Upbeat Results; GT Biopharma Shares Slide   Benzinga
Nov 8, 2021
10:09AM EST  Mid-Morning Market Update: Markets Rise; Coty Posts Upbeat Earnings   Benzinga
07:33AM EST  GT Biopharma CEO Anthony Cataldo And CFO Michael Handelman To Depart; Co. Initiates Search Process   Benzinga
07:30AM EST  GT Biopharma Announces Executive Leadership Transition to Implement Next Phase   PR Newswire
Sep 20, 2021
07:05AM EDT  GT BioPharma Highlights Presentation Of Camelid TriKE Nanobody Platform At ESMO Congress 2021   Benzinga
07:01AM EDT  GT BioPharma's Next Generation Camelid TriKE(r) Nanobody Platform Highlighted   PR Newswire
Sep 15, 2021
07:13AM EDT  GT Reports Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial Immunotherapy For Refractory Cancers   RTTNews
07:02AM EDT  GT Biopharma Announces Updated Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial An Investigational Immunotherapy For Refractory Cancers To Be Presented at ESMO Congress 2021   Benzinga
07:01AM EDT  Monotherapy TriKE(tm) Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021   PR Newswire
Sep 13, 2021
07:02AM EDT  GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager   PR Newswire
Sep 9, 2021
07:08AM EDT  GT Biopharma Announces Issuance Of Two New Patents Covering TriKE Platform Technologies   Benzinga
07:01AM EDT  GT Biopharma Announces Issuance of Two New Patents Covering TriKE(r) Platform   PR Newswire
Sep 8, 2021
12:29PM EDT  GT Biopharma to Present at Upcoming September Investor Conferences   PR Newswire
Aug 23, 2021
07:01AM EDT  GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of   PR Newswire
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
07:37AM EDT  GT Biopharma Announces Positive Interim Data Results Demonstrating Substantial Reduction In AML/MDS Cancer Cells   RTTNews
07:30AM EDT  GT Biopharma Provides Second Quarter 2021 Business Update   PR Newswire
04:12AM EDT  Earnings Scheduled For August 13, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 6, 2021
08:01AM EDT  GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results   PR Newswire
Aug 3, 2021
07:10AM EDT  GT Biopharma Announces Preclinical Results For GTB-5550 B7H3 TriKE   Benzinga
07:02AM EDT  GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE(tm)   PR Newswire
Jul 28, 2021
08:14AM EDT  GT Biopharma Announces $16M In Warrant Exercise Proceeds   Benzinga
08:02AM EDT  GT Biopharma Announces $16 million in Warrant Exercise Proceeds   PR Newswire
Jul 7, 2021
08:02AM EDT  GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller   PR Newswire
Jun 24, 2021
08:01AM EDT  GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global   PR Newswire
Jun 23, 2021
08:01AM EDT  GT Biopharma Highlights Presentation Of Interim GTB-3550 Trike Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference   Benzinga
08:01AM EDT  GT Biopharma Announces Interim GTB-3550 Trike(tm) Monotherapy Clinical Trial   PR Newswire
Jun 21, 2021
08:01AM EDT  Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference   PR Newswire
Jun 16, 2021
08:02AM EDT  GT Biopharma to Present at Raymond James Human Health Innovation Conference   PR Newswire
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 8, 2021
08:15AM EDT  GT Biopharma To Be Added To Russell 2000 Index On June 28   Benzinga
08:01AM EDT  GT Biopharma to be Added to the Russell 2000(r) Index   PR Newswire
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
Jun 2, 2021
08:20AM EDT  The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements   Benzinga
May 24, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021   Benzinga
06:12AM EDT  HC Wainwright & Co. Initiates Coverage On GT Biopharma with Buy Rating, Announces Price Target of $25   Benzinga
May 18, 2021
09:51AM EDT  GT Biopharma To Host Interim GTB-3550 TriKE Data Review Call With Dr. Jeffrey Miller On May 19 At 4 p.m. EDT   Benzinga
09:51AM EDT  GT Biopharma to Host Interim GTB-3550 TriKE(tm) Data Review Call with Dr.   PR Newswire
May 17, 2021
06:55PM EDT  GT Biopharma Reports First Quarter 2021 Results   PR Newswire
May 12, 2021
07:15AM EDT  GT Biopharma Announces Update On Commencement Of GTB-3550 TriKE Monotherapy Phase 2 Clinical Trial   RTTNews
07:03AM EDT  GT Biopharma Says Announces Update On Commencement Of GTB-3550 TriKE Monotherapy Phase 2 Clinical Trial; Says Indications Of Anti-Tumor Activity During Phase 1 Resulted In 'refocusing of the Phase 2 design of the clinical trial'   Benzinga
07:01AM EDT  Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE(tm) Product Candidates   PR Newswire
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 26, 2021
07:08AM EDT  GT Biopharma Names Gregory Berk Chief Medical Officer And Jeffrey Miller To Consulting Chief Scientific Officer   RTTNews
07:01AM EDT  GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical   PR Newswire
Apr 19, 2021
07:29AM EDT  GT Biopharma Q4 Net Loss $14.9 Mln Vs Loss Of $1.5 Mln Last Year   RTTNews
07:17AM EDT  GT Biopharma Q4 EPS $(3.40)   Benzinga
07:01AM EDT  GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business   PR Newswire
Apr 13, 2021
12:11PM EDT  GT Biopharma shares were trading higher after B. Roley FBR initiated coverage on the stock with a Buy rating and announced a price target of $21 per share.   Benzinga
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021   Benzinga
07:08AM EDT  B. Riley FBR Initiates Coverage On GT Biopharma with Buy Rating, Announces Price Target of $21   Benzinga
Apr 12, 2021
08:23AM EDT  GT Biopharma Announces Addnl Interim Results From GTB-3550 TriKE Phase I/II Clinical Trial For MDS And AML   RTTNews
08:06AM EDT  GT Biopharma Announces Interim Results From GTB-3550 TriKE Monotherapy   Benzinga
08:01AM EDT  GT Biopharma Announces GTB-3550 TriKE(tm) Monotherapy Rescues and Restores NK   PR Newswire
Apr 8, 2021
08:36AM EDT  GT Biopharma Enrolls Patient 10 In GTB-3550 TriKE Phase I/II Clinical Trial   RTTNews
08:02AM EDT  GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE(tm) Phase   PR Newswire
08:02AM EDT  GT Biopharma Announces Enrollment Of Patient 10 In GTB-3550 TriKE Phase I/II Clinical Trial   Benzinga
Mar 29, 2021
07:01AM EDT  GT Biopharma's TriKE(tm) Interim Clinical Trial Results Presented At Innate   PR Newswire
Mar 17, 2021
10:40AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2021   Benzinga
09:39AM EDT  GT Biopharma's GTB-3550 Cuts Bone Marrow Blasts In High-Risk Patients With Hematological Malignancies   Benzinga
08:10AM EDT  GT Biopharma Reports Updated Interim GTB-3550 Trike Trial Results: 'Up to 63.7% Reduction in Bone Marrow Blast Levels, Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance'   Benzinga
08:03AM EDT  GT Biopharma Highlights Updated Interim GTB-3550 Trike Clinical Trial Results   Benzinga
08:01AM EDT  GT Biopharma Announces Updated Interim GTB-3550 Trike(tm) Clinical Trial Results   PR Newswire
07:25AM EDT  Roth Capital Initiates Coverage On GT Biopharma with Buy Rating, Announces Price Target of $25   Benzinga
Mar 10, 2021
08:02AM EST  GT Biopharma to Present at The Virtual 33rd Annual Roth Conference   PR Newswire
Mar 8, 2021
08:47AM EST  GT Biopharma Announces Preclinical Results For Its ROR1 TriKE(tm) As A   PR Newswire
08:47AM EST  GT Biopharma Announces Preclinical Results For ROR1 TriKE As Treatment For Prostate Cancer   RTTNews
Mar 4, 2021
08:31AM EST  Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE(tm), a Novel NK Cell Therapeutic Cancer Treatment   PR Newswire
Feb 18, 2021
08:10AM EST  GT Biopharma Transfers TriKE Manufacturing To Cytovance Biologics   RTTNews
08:06AM EST  GT Biopharma Transfers TriKE Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials   Benzinga
08:01AM EST  Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials   PR Newswire
Feb 16, 2021
08:00AM EST  GT Biopharma Announces Closing of $23.7 Million Public Offering   Business Wire
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
08:00AM EST  GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market   Business Wire
Jan 19, 2021
09:04AM EST  GT Biopharma Appoints Two New Independent Directors   PR Newswire
Jan 12, 2021
10:01AM EST  GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550   PR Newswire
Jan 4, 2021
09:45AM EST  GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call   PR Newswire
Dec 28, 2020
09:35AM EST  GT Biopharma Announces TriKE(tm) For The Treatment Of Breast And GI Cancers   PR Newswire
Dec 21, 2020
11:01AM EST  GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE(tm) REDUCES CANCER CELLS BY   PR Newswire
Dec 17, 2020
09:20AM EST  GT Biopharma, Cytovance Biologics Announce Milestone Achievement   RTTNews
09:15AM EST  GT Biopharma And Cytovance Biologics Announce Milestone Achievement   PR Newswire
Dec 14, 2020
09:05AM EST  GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC